Andreas Hillarp

  • Researcher; PhD

Publications 2023

Hillarp A, Holme PA, Wåland EP, Le MS, Henriksson CE, Tjønnfjord GE, Måseide RJ (2023)
Report on 4 cases with decreased recovery due to neutralizing antibodies specific for PEGylated recombinant factor VIII
J Thromb Haemost, 21 (10), 2771-2775
DOI 10.1016/j.jtha.2023.07.019, PubMed 37543216

Jørgensen OJ, Steineger JE, Hillarp A, Pareli Wåland E, Holme PA, Heimdal K, Dheyauldeen S (2023)
Elevated FVIII levels in hereditary hemorrhagic telangiectasia: Implications for clinical management
Laryngoscope Investig Otolaryngol, 9 (1), e1196
DOI 10.1002/lio2.1196, PubMed 38362186

Publications 2022

Bauça JM, Ajzner É, Cadamuro J, Hillarp A, Kristoffersen AH, Meijer P, Working Group on the Postanalytical Phase of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) (2022)
An international study on activated partial thromboplastin time prolongation. Part 1: Analytical results
Clin Chim Acta, 535, 167-173
DOI 10.1016/j.cca.2022.08.024, PubMed 36041550

Bauça JM, Ajzner É, Cadamuro J, Hillarp A, Kristoffersen AH, Meijer P, Working Group on the Postanalytical Phase of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) (2022)
An international study on activated partial thromboplastin time prolongation. Part 2: Interpretative commenting
Clin Chim Acta, 535, 174-179
DOI 10.1016/j.cca.2022.08.026, PubMed 36055391

Bian L, Baghaei F, Antovic J, Fagerberg Blixter I, Hillarp A, Strandberg K, Willman D, L Lindahl T (2022)
[Routine screening with APTT is not indicated before surgery]
Lakartidningen, 119
PubMed 35713306

Boknäs N, Laine C, Hillarp A, Macwan AS, Gustafsson KM, Lindahl TL, Holmström M (2022)
Associations between hemostatic markers and mortality in COVID-19 - Compounding effects of D-dimer, antithrombin and PAP complex
Thromb Res, 213, 97-104
DOI 10.1016/j.thromres.2022.03.013, PubMed 35316719

Taune V, Skeppholm M, Ågren A, Wikman A, Hillarp A, Wallén H (2022)
Rapid Detection of Apixaban by a ROTEM-Based Approach and Reversibility with Andexanet Alfa or DOAC-Stop
TH Open, 6 (3), e238-e247
DOI 10.1055/s-0042-1751072, PubMed 36046206

Publications 2021

Cadamuro J, Hillarp A, Unger A, von Meyer A, Bauçà JM, Plekhanova O, Linko-Parvinen A, Watine J, Leichtle A, Buchta C, Haschke-Becher E, Eisl C, Winzer J, Kristoffersen AH (2021)
Presentation and formatting of laboratory results: a narrative review on behalf of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group "postanalytical phase" (WG-POST)
Crit Rev Clin Lab Sci, 58 (5), 329-353
DOI 10.1080/10408363.2020.1867051, PubMed 33538219

Larsson SM, Hellström-Westas L, Hillarp A, Åkeson PK, Domellöf M, Askelöf U, Götherström C, Andersson O (2021)
Haemoglobin and red blood cell reference intervals during infancy
Arch Dis Child, 107 (4), 351-358
DOI 10.1136/archdischild-2021-321672, PubMed 34674992

Sonesson A, Malm J, Rylander L, Giwercman A, Hillarp A (2021)
Serum amyloid P component: a new biomarker for low sperm concentration?
Asian J Androl, 23 (5), 450-455
DOI 10.4103/aja.aja_7_21, PubMed 33723096

Publications 2020

Hillarp A, Strandberg K, Gustafsson KM, Lindahl TL (2020)
Unveiling the complex effects of direct oral anticoagulants on dilute Russell's viper venom time assays
J Thromb Haemost, 18 (8), 1866-1873
DOI 10.1111/jth.14829, PubMed 32294291

Larsson SM, Hillarp A, Karlsland Åkeson P, Hellström-Westas L, Domellöf M, Askelöf U, Götherström C, Andersson O (2020)
Soluble Transferrin Receptor during infancy and reference intervals for the Roche Cobas platform
Int J Lab Hematol, 43 (3), 378-386
DOI 10.1111/ijlh.13391, PubMed 33217104

Publications 2019

Larsson SM, Hillarp A, Hellström-Westas L, Domellöf M, Lundahl T, Andersson O (2019)
When age really matters; ferritin reference intervals during infancy revisited
Scand J Clin Lab Invest, 79 (8), 590-594
DOI 10.1080/00365513.2019.1681028, PubMed 31642699

Publications 2018

Hillarp A, Strandberg K, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Lindahl TL (2018)
Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays
Scand J Clin Lab Invest, 78 (7-8), 575-583
DOI 10.1080/00365513.2018.1522664, PubMed 30278787

Publications 2017

Kristoffersen AH, Ajzner E, Bauça JM, Carraro P, Faria AP, Hillarp A, Rogic D, Sozmen EY, Watine J, Meijer P, Sandberg S (2017)
Pre- and post-test probabilities of venous thromboembolism and diagnostic accuracy of D-dimer, estimated by European clinicians working in emergency departments
Thromb Res, 159, 19-23
DOI 10.1016/j.thromres.2017.09.012, PubMed 28950216

Przybyla B, Pinomäki A, Petäjä J, Joutsi-Korhonen L, Strandberg K, Hillarp A, Öhlin AK, Ruutu T, Volin L, Lassila R (2017)
Coordinated responses of natural anticoagulants to allogeneic stem cell transplantation and acute GVHD - A longitudinal study
PLoS One, 12 (12), e0190007
DOI 10.1371/journal.pone.0190007, PubMed 29272282

Publications 2016

Doma SA, Hillarp A, Pajič T, Andoljšek D, Černelč P, Preldžnik Zupan I (2016)
Concurrent acquired inhibitors to factor VIII and IX, a laboratory artifact: a case report
Biochem Med (Zagreb), 26 (2), 279-84
DOI 10.11613/BM.2016.033, PubMed 27346976

Winstedt D, Solomon C, Hillarp A, Lundahl T, Schött U (2016)
Intraoperative Hydroxyethyl Starch and its Effects on Different Fibrinogen Measurements
Clin Appl Thromb Hemost, 22 (7), 641-7
DOI 10.1177/1076029616632904, PubMed 26893443

Publications 2015

Dauti F, Hjaltalin Jonsson M, Hillarp A, Bentzer P, Schött U (2015)
Perioperative changes in PIVKA-II
Scand J Clin Lab Invest, 75 (7), 562-7
DOI 10.3109/00365513.2015.1058521, PubMed 26198297

Foltyn Zadura A, Memon AA, Stojanovich L, Perricone C, Conti F, Valesini G, Bogdanovic G, Hillarp A, Shoenfeld Y, Sundquist J, Leffler J, Svensson PJ, Trouw LA, Blom AM (2015)
Factor H Autoantibodies in Patients with Antiphospholipid Syndrome and Thrombosis
J Rheumatol, 42 (10), 1786-93
DOI 10.3899/jrheum.150185, PubMed 26276971

Isma N, Sutton R, Hillarp A, Strandberg K, Melander O, Fedorowski A (2015)
Higher levels of von Willebrand factor in patients with syncope due to orthostatic hypotension
J Hypertens, 33 (8), 1594-601
DOI 10.1097/HJH.0000000000000595, PubMed 26136066

Lindahl TL, Wallstedt M, Gustafsson KM, Persson E, Hillarp A (2015)
More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate
Thromb Res, 135 (3), 544-7
DOI 10.1016/j.thromres.2014.12.019, PubMed 25596769

Potgieter JJ, Damgaard M, Hillarp A (2015)
One-stage vs. chromogenic assays in haemophilia A
Eur J Haematol, 94 Suppl 77, 38-44
DOI 10.1111/ejh.12500, PubMed 25560793

Timm A, Hillarp A, Philips M, Goetze JP (2015)
Comparison of automated von Willebrand factor activity assays
Thromb Res, 135 (4), 684-91
DOI 10.1016/j.thromres.2015.01.027, PubMed 25661290

Publications 2014

Armstrong E, Hillarp A (2014)
Assay discrepancy in mild haemophilia A
Eur J Haematol Suppl, 76, 48-50
DOI 10.1111/ejh.12374, PubMed 24957107

Publications 2013

Klintman J, Hillarp A, Berntorp E, Astermark J (2013)
Long-term anti-FVIII antibody response in Bethesda-negative haemophilia A patients receiving continuous replacement therapy
Br J Haematol, 163 (3), 385-92
DOI 10.1111/bjh.12540, PubMed 24032553

Publications 2012

Foltyn Zadura A, Zipfel PF, Bokarewa MI, Sturfelt G, Jönsen A, Nilsson SC, Hillarp A, Saxne T, Trouw LA, Blom AM (2012)
Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome
Arthritis Res Ther, 14 (4), R185
DOI 10.1186/ar4016, PubMed 22894814

Karlsson O, Sporrong T, Hillarp A, Jeppsson A, Hellgren M (2012)
Prospective longitudinal study of thromboelastography and standard hemostatic laboratory tests in healthy women during normal pregnancy
Anesth Analg, 115 (4), 890-8
DOI 10.1213/ANE.0b013e3182652a33, PubMed 22822194

Knobe K, Tedgård U, Ek T, Sandström PE, Hillarp A (2012)
Lupus anticoagulants in two children--bleeding due to nonphospholipid-dependent antiprothrombin antibodies
Eur J Pediatr, 171 (9), 1383-7
DOI 10.1007/s00431-012-1737-1, PubMed 22527568

Lind-Halldén C, Dahlen A, Hillarp A, Zöller B, Dahlbäck B, Halldén C (2012)
Small and large PROS1 deletions but no other types of rearrangements detected in patients with protein S deficiency
Thromb Haemost, 108 (1), 94-100
DOI 10.1160/TH12-01-0040, PubMed 22627709

Publications 2011

Knobe K, Astermark J, Berntorp E, Hillarp A, Strandberg K, Svensson PJ (2011)
[Rare hereditary types of hemophilia. Bleeding symptoms, family history and laboratory analyses indicates diagnosis]
Lakartidningen, 108 (38), 1819-23
PubMed 22111212

Lassila R, Antovic JP, Armstrong E, Baghaei F, Dalsgaard-Nielsen J, Hillarp A, Holme PA, Holmström M, Johnsson H, Joutsi-Korhonen L, Sandset PM (2011)
Practical viewpoints on the diagnosis and management of heparin-induced thrombocytopenia
Semin Thromb Hemost, 37 (3), 328-36
DOI 10.1055/s-0031-1274516, PubMed 21455867

Lassila R, Holme PA, Landorph A, Petrini P, Onundarson PT, Hillarp A (2011)
Nordic Haemophilia Council's practical guidelines on diagnosis and management of von Willebrand disease
Semin Thromb Hemost, 37 (5), 495-502
DOI 10.1055/s-0031-1281034, PubMed 22102192

Sonesson A, Hillarp A, Giwercman A, Malm J (2011)
Determination of serum amyloid P component in seminal plasma and correlations with serum hormone levels in young, healthy men
Scand J Clin Lab Invest, 71 (7), 569-75
DOI 10.3109/00365513.2011.596567, PubMed 21988589

Publications 2010

Höög CM, Broström O, Lindahl TL, Hillarp A, Lärfars G, Sjöqvist U (2010)
Bleeding from gastrointestinal angioectasias is not related to bleeding disorders - a case control study
BMC Gastroenterol, 10, 113
DOI 10.1186/1471-230X-10-113, PubMed 20920209

Lindahl TL, Baghaei F, Blixter IF, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Hillarp A, Expert Group on Coagulation of the External Quality Assurance in Laboratory Medicine in Sweden (2010)
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays
Thromb Haemost, 105 (2), 371-8
DOI 10.1160/TH10-06-0342, PubMed 21103660

Sveinsdottir SV, Hillarp A, Astermark J, Svensson PJ, Berntorp E (2010)
[Von Willebrand disease--from biochemistry to clinical practice]
Lakartidningen, 107 (34), 1923-7
PubMed 20960954

Publications 2009

Rask O, Hillarp A, Berntorp E, Ljung R (2009)
Anti-prothrombin antibodies are associated with thrombosis in children
Thromb Res, 125 (1), 19-24
DOI 10.1016/j.thromres.2009.02.007, PubMed 19303627

Själander A, Johansson L, Hillarp A, Bergqvist D, Tengborn L, Svensson P (2009)
[Thrombocytopenia can be HIT. Heparin treatment can cause low life-threatening thrombocyte levels]
Lakartidningen, 106 (10), 682-5
PubMed 19418688

Wieloch M, Hillarp A, Strandberg K, Nilsson C, Svensson PJ (2009)
Comparison and evaluation of a Point-of-care device (CoaguChek XS) to Owren-type prothrombin time assay for monitoring of oral anticoagulant therapy with warfarin
Thromb Res, 124 (3), 344-8
DOI 10.1016/j.thromres.2009.03.007, PubMed 19423152

Publications 2008

Gøtze JP, Hillarp A, Lindblom A, Björk P, Strandberg K, Nielsen LB (2008)
[New marker in thrombotic thrombocytopenic purpura]
Ugeskr Laeger, 170 (33), 2446-9
PubMed 18761827

Gøtze JP, Lindblom A, Björk P, Nielsen LB, Strandberg K, Manea M, Hillarp A (2008)
[ADAMTS13--actor and marker in thrombotic microangiopathy]
Lakartidningen, 105 (15), 1092-5
PubMed 18561751

Lethagen S, Hillarp A, Ekholm C, Mattson E, Halldén C, Friberg B (2008)
Distribution of von Willebrand factor levels in young women with and without bleeding symptoms: influence of ABO blood group and promoter haplotypes
Thromb Haemost, 99 (6), 1013-8
DOI 10.1160/TH07-06-0419, PubMed 18521502

Radulovic V, Svensson P, Hillarp A, Berntorp E (2008)
[Bleeding time determination is out of date. A non-reliable method which should not be used in routine care]
Lakartidningen, 105 (17-18), 1278-83
PubMed 18561529

Publications 2007

Malm J, Sonesson A, Hellman J, Bjartell A, Frohm B, Hillarp A (2007)
The pentraxin serum amyloid P component is found in the male genital tract and attached to spermatozoa
Int J Androl, 31 (5), 508-17
DOI 10.1111/j.1365-2605.2007.00800.x, PubMed 17822421

Publications 2006

Strandberg K, Lethagen S, Andersson K, Carlson M, Hillarp A (2006)
Evaluation of a rapid automated assay for analysis of von Willebrand ristocetin cofactor activity
Clin Appl Thromb Hemost, 12 (1), 61-7
DOI 10.1177/107602960601200110, PubMed 16444436

Publications 2005

Johansson AM, Hillarp A, Säll T, Zöller B, Dahlbäck B, Halldén C (2005)
Large deletions of the PROS1 gene in a large fraction of mutation-negative patients with protein S deficiency
Thromb Haemost, 94 (5), 951-7
DOI 10.1160/TH05-06-0392, PubMed 16363235

Publications 2004

Björkman A, Burtscher IM, Svensson PJ, Hillarp A, Besjakov J, Benoni G (2004)
Factor V Leiden and the prothrombin 20210A gene mutation and osteonecrosis of the knee
Arch Orthop Trauma Surg, 125 (1), 51-5
DOI 10.1007/s00402-004-0760-8, PubMed 15723247

Björkman A, Svensson PJ, Hillarp A, Burtscher IM, Rünow A, Benoni G (2004)
Factor V leiden and prothrombin gene mutation: risk factors for osteonecrosis of the femoral head in adults
Clin Orthop Relat Res (425), 168-72
PubMed 15292803

Hillarp A (2004)
[Acetylsalicylic acid resistance--clinical diagnosis with unclear mechanism]
Lakartidningen, 101 (45), 3504-6, 3508-9
PubMed 15575422

Hillarp A, Egberg N, Nordin G, Stigendal L, Fagerberg I, Lindahl TL (2004)
Local INR calibration of the Owren type prothrombin assay greatly improves the intra- and interlaboratory variation. A three-year follow-up from the Swedish national external quality assessment scheme
Thromb Haemost, 91 (2), 300-7
DOI 10.1160/TH03-07-0419, PubMed 14961158

Jonsson M, Hillarp A, Svensson P (2004)
Comparison between CoaguChek S- and Owren-type prothrombin time assay for monitoring anticoagulant therapy
Thromb Res, 114 (2), 83-9
DOI 10.1016/j.thromres.2004.04.010, PubMed 15306149

Lindahl TL, Egberg N, Hillarp A, Ødegaard OR, Edlund B, Svensson J, Sandset PM, Rånby M (2004)
INR calibration of Owren-type prothrombin time based on the relationship between PT% and INR utilizing normal plasma samples
Thromb Haemost, 91 (6), 1223-31
DOI 10.1160/TH03-07-0456, PubMed 15175811

Lindahl TL, Egeberg N, Hillarp A, Ødegaard OR, Edlund B, Svensson J, Sandset PM, Rånby M (2004)
INR calibration of owren-type prothombrin time based on the relationship between PT\% and INR utilizing normal plasma samples
In Thrombosis and haemostasis, Schattauer, Stuttgart, 91(2004)6, S. 1223-1231
BIBSYS 051926776

Ohlin AK, Holm J, Hillarp A (2004)
Genetic variation in the human thrombomodulin promoter locus and prognosis after acute coronary syndrome
Thromb Res, 113 (5), 319-26
DOI 10.1016/j.thromres.2004.03.010, PubMed 15183044

Publications 2003

Blom AM, Kask L, Ramesh B, Hillarp A (2003)
Effects of zinc on factor I cofactor activity of C4b-binding protein and factor H
Arch Biochem Biophys, 418 (2), 108-18
DOI 10.1016/, PubMed 14522582

Hillarp A, Palmqvist B, Lethagen S, Villoutreix BO, Mattiasson I (2003)
Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke
Thromb Res, 112 (5-6), 275-83
DOI 10.1016/j.thromres.2003.12.005, PubMed 15041270

Persson KE, Dahlbäck B, Hillarp A (2003)
Diagnosing protein S deficiency: analytical considerations
Clin Lab, 49 (3-4), 103-10
PubMed 12705691

Publications 2002

Hillarp A, Egberg N, Fagerberg I, Lindahl TL, Nordin G, Stigendal L (2002)
[Less variation in laboratory results after the introduction of INR. Differences between hospital laboratories and laboratories within primary health care are levelled out]
Lakartidningen, 99 (50), 5068-70, 5073-4
PubMed 12572298

Kask L, Hillarp A, Ramesh B, Dahlbäck B, Blom AM (2002)
Structural requirements for the intracellular subunit polymerization of the complement inhibitor C4b-binding protein
Biochemistry, 41 (30), 9349-57
DOI 10.1021/bi025980+, PubMed 12135356

Page visits: 1793